Eligible patients may be able to get Wynzora for as little as

$35*

Get details

*See rebate card for details.

$

Person on phone laying in a concrete circle.

Wynzora is designed for ease of use in daily routines1

https://www.wynzora.com/wp-content/uploads/2021/08/droplet-medallion.svg

The convenience and ease of use of Wynzora achieved high scores in clinical trials1

For patients with psoriasis, convenience and cosmetic characteristics of topical treatments are key motivators for continued use1,2

Patient-perceived treatment convenience was assessed on a numerical scale in the following categories1:

Ease of application hand icon Greasiness of application hand icon Moisturization of skin icon Disruption of daily routing checklist Greasy residue hand

PTCS: Psoriasis Treatment Convenience Scale.

Ease of use influences patient adherence

Up to 75% of patients are non-adherent to topical treatments for plaque psoriasis, and the most frequent reasons for discontinuation include poor cosmetic characteristics and time-consuming nature.2,4

Cosmetic acceptability and ease of use affect treatment preference and adherence, with patients generally preferring less messy treatments that are easy to apply.5

—Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25(s4):9-14

arrow

Indication and Use

Wynzora® (calcipotriene and betamethasone dipropionate) Cream is indicated for plaque psoriasis in adults. It is not known if Wynzora Cream is safe and effective in children.

Important Safety Information

  • Wynzora Cream is for topical use only.
  • Patients should not use more than 100g of Wynzora Cream per week.
  • Wynzora Cream should not be used near or in the mouth, eyes, or intravaginally.
  • Patients should avoid using Wynzora Cream on the face, groin, or armpits, or if they have atrophy at the treatment site.
  • Patients should apply Wynzora Cream to the affected areas of the skin once a day for up to 8 weeks.
  • Patients should discontinue use once the plaque psoriasis is under control.
  • Patients should not use with occlusive dressings.
  • Hypercalcemia and hypercalciuria have been observed with use of topical calcipotriene.
  • Wynzora Cream can cause reversible HPA axis suppression with the potential for clinical glucocorticosteroid insufficiency during and after withdrawal of treatment.
  • Wynzora Cream may cause vision problems, including increasing the risk of cataracts and glaucoma.
  • It is not known whether Wynzora Cream may harm your unborn baby.
  • Breastfeeding women should not apply Wynzora Cream directly to the nipple and areola.
  • It is not known whether topically administered calcipotriene and betamethasone dipropionate is absorbed in human milk.

Please see Full Prescribing Information for Wynzora.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References: 1. Præstegaard M, Vestbjerg B, Selmer J, Holm-Larsen T. Phase 3 trial demonstrates superior patient treatment convenience of MC2-01 calcipotriene plus betamethasone dipropionate cream compared to current topical suspension. J of Skin. 2020;4(5):s62. 2. Devaux S, Castela A, Archier E, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(s3):61-67. 3. Data on file. MC2 Therapeutics. 4. Armstrong AW. Practice Gaps: failure to maximize patient adherence strategies in clinical practice. Arch Dermatol. 2010;146(12):1430-1431. 5. Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;2(suppl 4):9-14. doi:10.1111/j.1468-3083.2011.04060.x